Related Experiment Video
Updated: May 4, 2026

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
Published on: May 3, 2021
Pattern of presentation and outcome of ophthalmic rhabdomyosarcoma in Ibadan
1Department of Ophthalmology, College of Medicine, University of Ibadan, Ibadan, Nigeria. yemifash2000@yahoo.com
Insights
Ophthalmic rhabdomyosarcoma (RMS) in Nigerian children presents challenges due to late diagnosis and poor treatment adherence. Improving outcomes requires enhanced public awareness and financial support for treatment.
Area of Science:
- Ophthalmology
- Pediatric Oncology
- Sarcoma Research
Background:
- Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma and primary orbital malignancy in children.
- Ophthalmic RMS studies are limited in Nigeria and Africa.
- This study details the pattern and treatment outcomes of ophthalmic RMS in Ibadan.
Purpose of the Study:
- To describe the demographic and morphologic patterns of ophthalmic rhabdomyosarcoma.
- To evaluate the treatment outcomes for ophthalmic RMS in Ibadan.
- To identify factors contributing to poor treatment outcomes.
Main Methods:
- Retrospective, non-comparative, consecutive, interventional analysis.
- Study conducted over 20 years in an ocular oncology unit.
- Analysis of 22 patient records with ophthalmic RMS.
Main Results:
- Embryonal RMS was the most common subtype (72.7%).
- All patients presented with visual loss, orbital swelling, and proptosis.
- Treatment outcomes were poor, with a high rate of mortality and loss to follow-up (68.2%).
Conclusions:
- Ophthalmic RMS demographics and morphology in Ibadan align with global data.
- Poor treatment outcomes are linked to late presentation and inconsistent treatment.
- Improving outcomes necessitates strengthened health insurance and public awareness for early detection.
Background:
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma, and the commonest primary orbital malignancy in children. Studies on ophthalmic RMS are scanty in Nigeria, and other parts of Africa. This study thus describes the pattern of ophthalmic RMS in Ibadan and treatment outcome.
Method:
A retrospective, non-comparative, consecutive, interventional analysis of patients with ophthalmic RMS in an ocular oncology unit of a teaching hospital over 20 years was carried out.
Results:
Records of 22 patients, 15 males and 7 females, aged 2 months to 50 years (Median 7 years, Range 5-13 years) were analyzed. All patients presented with visual loss, orbital swelling and proptosis. Histological examination revealed embryonal RMS in 16 (72.7%) patients, alveolar in three (13.6%), pleomorphic in two (9.1%) and "not otherwise stated" in one (4.5%). Treatment outcome was poor as only two (9.1%) patients remained tumour-free 12 and 36 months after diagnosis. Three (13.6%) patients died on admission, while two (9.1%) patients are presently undergoing treatment. Fifteen (68.2%) patients were lost to follow-up, financial constraint and perceived poor response to treatment being the main reasons for incomplete and inconsistent treatment regimen and resultant poor outcome.
Conclusion:
Demography and morphology of ophthalmic RMS in Ibadan is comparable to other studies. However, treatment outcome remains poor, mainly due to late presentation, incomplete and inconsistent treatment. Strengthening the national health insurance scheme to cater for the indigent and increased public enlightenment on early presentation of cases may go a long way in improving the outcome in our patients.
More Related Videos
Related Concept Videos
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...

